Literature DB >> 17531838

The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology?

Aaron J Johnson1, Georgette L Suidan, Jeremiah McDole, Istvan Pirko.   

Abstract

Multiple sclerosis (MS) is the most common human demyelinating disease of the central nervous system. It is universally accepted that the immune system plays a major role in the pathogenesis of MS. For decades, CD4 T cells have been considered the predominant mediator of neuropathology in MS. This perception was largely due to the similarity between MS and CD4 T-cell-driven experimental allergic encephalomyelitis, the most commonly studied murine model of MS. Over the last decade, several new observations in MS research imply an emerging role for CD8 T cells in neuropathogenesis. In certain experimental autoimmune encephalomyelitis (EAE) models, CD8 T cells are considered suppressors of pathology, whereas in other EAE models, neuropathology can be exacerbated by adoptive transfer of CD8 T cells. Studies using the Theiler's murine encephalomyelitis virus (TMEV) model have demonstrated preservation of motor function and axonal integrity in animals deficient in CD8 T cells or their effector molecules. CD8 T cells have also been demonstrated to be important regulators of blood-brain barrier permeability. There is also an emerging role for CD8 T cells in human MS. Human genetic studies reveal an important role for HLA class I molecules in MS susceptibility. In addition, neuropathologic studies demonstrate that CD8 T cells are the most numerous inflammatory infiltrate in MS lesions at all stages of lesion development. CD8 T cells are also capable of damaging neurons and axons in vitro. In this chapter, we discuss the neuropathologic, genetic, and experimental evidence for a critical role of CD8 T cells in the pathogenesis of MS and its most frequently studied animal models. We also highlight important new avenues for future research.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531838     DOI: 10.1016/S0074-7742(07)79004-9

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  25 in total

1.  Theiler's virus infection: Pathophysiology of demyelination and neurodegeneration.

Authors:  Fumitaka Sato; Hiroki Tanaka; Faris Hasanovic; Ikuo Tsunoda
Journal:  Pathophysiology       Date:  2011-02

2.  A dynamic in vitro BBB model for the study of immune cell trafficking into the central nervous system.

Authors:  Luca Cucullo; Nicola Marchi; Mohammed Hossain; Damir Janigro
Journal:  J Cereb Blood Flow Metab       Date:  2010-09-15       Impact factor: 6.200

3.  Brain atrophy in picornavirus-infected FVB mice is dependent on the H-2Db class I molecule.

Authors:  April M Huseby Kelcher; Pascal A Atanga; Jeffrey D Gamez; Luz M Cumba Garcia; Stephanie J Teclaw; Kevin D Pavelko; Slobodan I Macura; Aaron J Johnson
Journal:  FASEB J       Date:  2017-02-10       Impact factor: 5.191

4.  Rapid formation of extended processes and engagement of Theiler's virus-infected neurons by CNS-infiltrating CD8 T cells.

Authors:  Jeremiah R McDole; Steve C Danzer; Raymund Y K Pun; Yi Chen; Holly L Johnson; Istvan Pirko; Aaron J Johnson
Journal:  Am J Pathol       Date:  2010-09-02       Impact factor: 4.307

5.  Axonal degeneration as a self-destructive defense mechanism against neurotropic virus infection.

Authors:  Ikuo Tsunoda
Journal:  Future Virol       Date:  2008       Impact factor: 1.831

6.  Immunopathogenesis of multiple sclerosis.

Authors:  Michael K Racke
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

7.  Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.

Authors:  Mark S Freedman; Johanne M Kaplan; Silva Markovic-Plese
Journal:  J Clin Cell Immunol       Date:  2013-07-08

8.  Targeting myelin proteolipid protein to the MHC class I pathway by ubiquitination modulates the course of experimental autoimmune encephalomyelitis.

Authors:  Diethilde J Theil; Jane E Libbey; Fernando Rodriguez; J Lindsay Whitton; Ikuo Tsunoda; Tobias J Derfuss; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2008-11-15       Impact factor: 3.478

Review 9.  Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor.

Authors:  B N Dittel
Journal:  Br J Pharmacol       Date:  2007-10-08       Impact factor: 8.739

10.  Increased numbers of IL-7 receptor molecules on CD4+CD25-CD107a+ T-cells in patients with autoimmune diseases affecting the central nervous system.

Authors:  Nalini Kumar Vudattu; Sharon Kuhlmann-Berenzon; Mohsen Khademi; Vicki Seyfert; Thomas Olsson; Markus J Maeurer
Journal:  PLoS One       Date:  2009-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.